F Di Renzo - JoVE Visualize

Showing results (91-100 of 121) with videos related to

Pageof 13

Sort By:

Oncogene|March 29, 2000

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasM F Di Renzo, M Olivero, T Martone, et al.

International Journal of Cancer|July 27, 1999

Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC familyM Olivero, G Valente, A Bardelli, et al.

Oncogene|April 18, 1996

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomasR Ferracini, M Olivero, M F Di Renzo, et al.

International Reviews of Immunology|May 10, 2014

Sperm protein 17 is an oncofetal antigen: a lesson from a murine modelF Arnaboldi, A Menon, E Menegola, et al.

Oncogene|July 22, 1998

Overexpression of the RON gene in human breast carcinomaP Maggiora, S Marchio, M C Stella, et al.

Scientific Reports|April 17, 2020

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancerS Capellero, J Erriquez, C Melano, et al.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 20, 2011

Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memoryPasquale Molinaro, Davide Viggiano, Robert Nisticò, et al.

British Journal of Cancer|December 1, 1996

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomasM Olivero, M Rizzo, R Madeddu, et al.

Neuroendocrinology|April 23, 2004

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogsC Matrone, R Pivonello, A Colao, et al.

Gynecologic Oncology|June 24, 2015

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancerJ Erriquez, P Becco, M Olivero, et al.

Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:

Pageof 13

Oncogene|March 29, 2000

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasM F Di Renzo, M Olivero, T Martone, et al.

International Journal of Cancer|July 27, 1999

Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC familyM Olivero, G Valente, A Bardelli, et al.

Oncogene|April 18, 1996

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomasR Ferracini, M Olivero, M F Di Renzo, et al.

International Reviews of Immunology|May 10, 2014

Sperm protein 17 is an oncofetal antigen: a lesson from a murine modelF Arnaboldi, A Menon, E Menegola, et al.

Oncogene|July 22, 1998

Overexpression of the RON gene in human breast carcinomaP Maggiora, S Marchio, M C Stella, et al.

Scientific Reports|April 17, 2020

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancerS Capellero, J Erriquez, C Melano, et al.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 20, 2011

Na+ -Ca2+ exchanger (NCX3) knock-out mice display an impairment in hippocampal long-term potentiation and spatial learning and memoryPasquale Molinaro, Davide Viggiano, Robert Nisticò, et al.

British Journal of Cancer|December 1, 1996

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomasM Olivero, M Rizzo, R Madeddu, et al.

Neuroendocrinology|April 23, 2004

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogsC Matrone, R Pivonello, A Colao, et al.

Gynecologic Oncology|June 24, 2015

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancerJ Erriquez, P Becco, M Olivero, et al.

Pageof 13